Get the Stockscreener App
23.27
2.52%
-0.51
Spyre Therapeutics Inc stock is traded at $23.27, with a volume of 123.83K.
It is down -2.52% in the last 24 hours and up +45.88% over the past month.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
See More
Previous Close:
$23.78
Open:
$23.29
24h Volume:
123.83K
Relative Volume:
0.15
Market Cap:
$1.40B
Revenue:
$688.00K
Net Income/Loss:
$-170.19M
P/E Ratio:
-7.6308
EPS:
-3.0495
Net Cash Flow:
$-154.68M
1W Performance:
-5.93%
1M Performance:
+45.88%
6M Performance:
+53.41%
1Y Performance:
-34.02%
1-Day Range:
$23.01
$23.56
1-Week Range:
$22.42
$25.00
52-Week Range:
$10.91
$40.26
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Name
Spyre Therapeutics Inc
Sector
Industry
Phone
(617) 651-5940
Address
221 CRESCENT STREET, WALTHAM
Compare SYRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
23.16 | 1.84B | 688.00K | -170.19M | -154.68M | -3.0495 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.52 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
635.93 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
427.26 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
841.69 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.96 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-26-25 | Initiated | Deutsche Bank | Buy |
| Apr-08-25 | Initiated | Leerink Partners | Outperform |
| Mar-18-25 | Initiated | Wolfe Research | Outperform |
| Sep-04-24 | Initiated | Wedbush | Outperform |
| Jul-16-24 | Initiated | Evercore ISI | Outperform |
| May-02-24 | Initiated | Robert W. Baird | Outperform |
| Mar-01-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Dec-11-23 | Initiated | Guggenheim | Buy |
| Dec-11-23 | Initiated | Jefferies | Buy |
| May-04-20 | Initiated | Piper Sandler | Overweight |
| Mar-21-19 | Initiated | JP Morgan | Overweight |
| Sep-04-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Apr-24-18 | Initiated | Evercore ISI | Outperform |
| Mar-14-18 | Reiterated | Needham | Buy |
View All
Spyre Therapeutics Inc Stock (SYRE) Latest News
Will Spyre Therapeutics Inc. stock recover faster than peers2025 Retail Activity & Stock Market Timing Techniques - newser.com
Will Spyre Therapeutics Inc. (3920) stock see insider accumulationEarnings Miss & AI Driven Stock Price Forecasts - newser.com
Why Spyre Therapeutics Inc. stock is seen as undervaluedPortfolio Gains Summary & Breakout Confirmation Alerts - newser.com
Can a trend reversal in Spyre Therapeutics Inc. lead to recoveryTrade Exit Report & Consistent Profit Alerts - newser.com
What margin trends mean for Spyre Therapeutics Inc. stockLong Setup & Fast Gain Swing Trade Alerts - newser.com
Is Spyre Therapeutics Inc. (3920) stock inflation resilientEarnings Trend Report & Verified Technical Trade Signals - newser.com
Using data tools to time your Spyre Therapeutics Inc. exitPortfolio Profit Report & Precise Swing Trade Alerts - newser.com
Is Spyre Therapeutics Inc. (3920) stock at risk of policy regulationWeekly Investment Recap & Advanced Technical Signal Analysis - newser.com
What sentiment indicators say about Spyre Therapeutics Inc. stockJuly 2025 Trends & Free Low Drawdown Momentum Trade Ideas - newser.com
Why retail investors favor Spyre Therapeutics Inc. stock2025 Bull vs Bear & AI Powered Market Trend Analysis - newser.com
Is Spyre Therapeutics Inc. stock a buy for dividend growth2025 Big Picture & Free High Return Stock Watch Alerts - newser.com
Is a relief rally coming for Spyre Therapeutics Inc. holdersJuly 2025 Sentiment & Risk Controlled Stock Pick Alerts - newser.com
What insider purchases suggest about Spyre Therapeutics Inc. (3920) stockMarket Movers & AI Driven Stock Reports - newser.com
What dividend safety score for Spyre Therapeutics Inc. stockChart Signals & Free Accurate Trade Setup Notifications - newser.com
Can Spyre Therapeutics Inc. stock sustain free cash flow growthShare Buyback & AI Powered Market Entry Strategies - newser.com
Using Ichimoku Cloud for Spyre Therapeutics Inc. technicalsEarnings Overview Report & Weekly High Potential Stock Alerts - newser.com
Will Spyre Therapeutics Inc. (3920) stock beat international competitionMarket Risk Report & Low Risk High Win Rate Stock Picks - newser.com
Will Spyre Therapeutics Inc. stock deliver strong dividend growthJuly 2025 Highlights & Smart Swing Trading Alerts - newser.com
Will Spyre Therapeutics Inc. (3920) stock sustain uptrend momentumStop Loss & Expert Verified Movement Alerts - newser.com
Is Spyre Therapeutics Inc. (3920) stock undervalued after correction2025 Price Momentum & Consistent Growth Stock Picks - newser.com
Will Spyre Therapeutics Inc. stock maintain dividend yieldMarket Performance Summary & Weekly High Potential Alerts - newser.com
Will Spyre Therapeutics Inc. stock sustain high P E ratiosMarket Performance Report & Free Safe Entry Trade Signal Reports - newser.com
Is Spyre Therapeutics Inc. stock supported by innovation pipelineJuly 2025 Snapshot & Stock Portfolio Risk Control - newser.com
Why Spyre Therapeutics Inc. stock remains on watchlistsPortfolio Risk Report & Real-Time Market Trend Scan - newser.com
How to escape a deep drawdown in Spyre Therapeutics Inc.July 2025 Weekly Recap & Technical Analysis for Trade Confirmation - newser.com
Published on: 2025-11-02 03:35:20 - newser.com
Why Spyre Therapeutics Inc. stock remains undervalued2025 AllTime Highs & Smart Allocation Stock Tips - newser.com
Earnings visualization tools for Spyre Therapeutics Inc.July 2025 Patterns & Community Consensus Trade Alerts - newser.com
Published on: 2025-11-04 03:55:19 - newser.com
Spyre Therapeutics Inc Stock (SYRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.31%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):